
DNA Damage Response Modulators
Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1.
ATRN-119: Novel macrocyclic ATR inhibitor
-
Unique biomarkers identified for optimized patient selection
-
Differentiated, macrocyclic molecular structure
-
Potential for lower hematological toxicity versus other ATR inhibitors
-
Phase 1 clinical trial commenced 1Q, 2023
ATRN-W1051: Novel WEE1 inhibitor
-
Promising anti-tumor activity in tumor model
-
Potential for improved PK properties versus other WEE1 inhibitors
-
Excellent selectivity for WEE1 versus PLK1/2/3, potentially limiting off-target toxicity
-
Nanomolar anti-proliferative activity against multiple cancer cell lines
-
IND filing anticipated 4Q, 2023
DDR PIPELINE
MOLECULE
TARGET
INDICATION
BIOMARKER
Preclinical
IND-Enabling
Phase 1
Anticipated Milestones
ATRN-119
ATRn-1051
ATRN-354 1
APRE-DDRi
ATR
WEE1
ATR
DDR Target
Advanced solid tumors
Ovarian, breast, prostate
Ovarian, breast, prostate
Advanced solid tumors
Advanced solid tumors
Advanced solid tumors
Define biomarkers
BRAC1/2 + others
BRAC1/2 + others
CCNE amplification + others
Defined biomarkers
Defined biomarkers
Q1 2024: Phase 1 tolerability, PK
Q4: 2023 / Q1 2024: Ph1 initiation
Q4: 2023 / Q1 2024: Ph1 initiation
End of 2023: IND submission
Second half of 2024: IND submission
Mid-2024: Development candidate

DDR PIPELINE
